Replies to post #4271 on Enanta Pharmaceuticals Inc (ENTA)

[PioneerUniverse8]

I'd say that's not "short term" bullish :)

[jcrty]

While it indicates no partnership or other deal is at the finish line, a great indication. IMO many small insider buys as practiced these days are fluff and even a negative for their transparent effort to signal to shareholders. It's the $10,000 signaling buy from wealthy executives that is a disaster - an empty charade treated as a cost of doing (promotional) business. In contrast, a guy like Luly laying down this cash is significant.

Keep in mind per his ownership what his personal net worth in ENTA was a few years ago vs today. Having seen a pretty reasonable fortune slashed he's putting in real money to own more.

At the risk of taking it a bridge too far, the lack of a conf call combined with the purchase shows that the buy is all about the opportunity at this price rather than a desire to be noticed.

[dewophile]

Thx DD
The other SEC filing out today is the 10K:

https://ir.enanta.com/sec-filings/sec-filing/10-q/0000950170-25-018810

The costs in our immunology programs increased by $2.5 million primarily due to the scale-up and IND-enabling activities related to our KIT program and the initiation of preclinical studies for our STAT6 program.

Other Programs

Other program costs decreased by $2.2 million primarily due to the completion of the discovery and optimization activities related to our STAT6 program.

So while the company talks about scale up and ind enabling activities for kit as a 2025 event, it definitely started in earnest last quarter (no surprise). what is a bit unclear to me is they are most definitely in the discovery and optimization phase for stat6, yet in the 10k they say this is at "completion". I think they mean the costs are shifted from "early discovery" to the new stat 6 line item, but it is also possible they are further along and sandbagging a bit.
The big drop in early discovery program costs which is most of the 2,2M cited suggests to me they are probably winding down very early discovery, and perhaps the 3rd immunology program to be announced later this year may be the last. No complaints here I mean 4.4M in the same quarter last year on other early discovery might not sound like much, but at a 100M MC cutting down on this 18M annual burn is welcome news